Meet Meg Turner: From Competition Winner to Designing for Durkan and Beyond

For aspiring designers with a passion for hospitality design, the Durkan and Discover competition is a must-consider opportunity. This renowned competition offers more than just a chance to showcase talent; it provides participants with a valuable addition to their portfolio and an immersive experience in the intricate world of carpet design.

The impact of winning or placing in the Durkan and Discover competition cannot be overstated. It has the potential to catapult one’s career to new heights, opening doors to exciting prospects and opportunities. A shining example of this is Meg Turner, a previous winner, who not only had the honor of designing a collection for Durkan but also secured a coveted role as a field designer with the company.

Entering the competition should be embraced as an enjoyable and enlightening journey. It involves delving into research, studying existing carpet designs, and exploring avenues that can expand one’s creative boundaries. By immersing themselves in the process, participants gain a deeper understanding of the artistry and craftsmanship involved in creating captivating carpet designs for the hospitality industry.

Ultimately, the Durkan and Discover competition serves as a gateway to both personal and professional growth. It equips designers with invaluable insights, hones their skills, and establishes a compelling presence in the competitive world of hospitality design. So, for those seeking to leave their mark on the industry, embracing the challenge of this esteemed competition is a step towards realizing their dreams and shaping a successful career in the dynamic realm of hospitality design.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More